Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Prices Public Offering, Anticipates $8.9M in Net Proceeds

NEW YORK (GenomeWeb News) – BG Medicine today priced a public offering of common stock that is anticipated to bring in $8.9 million in net proceeds.

The Waltham, Mass.-based firm plans to offer 6,452,000 shares of its common stock at $1.55 per share. It also has granted the offering's underwriter a 30-day option to purchase up to an additional 967,800 shares to cover any overallotments.

Lazard Capital Markets is the sole book-running manager for the offering.

Net proceeds will be used for BG Medicine's operations, including further commercialization of its cardiovascular diagnostic tests in the US and in Europe, and developing new clinical claims and indications to expand its product pipeline. Proceeds will also go toward general corporate purposes, including capital expenditures, licensing of intellectual property, debt repayment, and working capital, it said.

BG Medicine raised $12.8 million in a public offering in early 2013. As of the end of 2013, the company had $7.8 million in cash and cash equivalents.

In Thursday morning trade on the Nasdaq, BG Medicine's shares dropped 19 percent to $1.56.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.